Figure 1.

Sample size flow chart. ^aExcluding neuropathological evidence of FTLD, Lewy bodies, ALS, prion disease, or argyrophilic grains, clinical evidence of DLB, Parkinson disease, Down syndrome, Huntington disease, prion disease, corticobasal syndrome, or progressive supranuclear palsy. ^bExcluding participants with sparse neuritic plaques; PART defined as no neuritic plaques; Alzheimer’s disease defined as moderate or frequent neuritic plaques.